<?xml version="1.0" encoding="UTF-8"?>
<p id="JVEv5-para-0038">Alternative targets for novel directly-acting anti-HBV agents include entry inhibitors such as Myrcludex B, capsid assembly disruptors (see summary of closing lecture) and HBV secretion inhibitors 
 <xref rid="JVEv5-bib-0004" ref-type="bibr">[4]</xref>. Gene silencing using synthetic siRNAs, gene and epigenetic modifiers with CRISPR/Cas and TALENs were also mentioned and will be discussed in more detail in later presentations.
</p>
